CN113134021A - 盐肤木果实或其提取物在制备防治药物性肝炎肝损伤药物中的应用 - Google Patents
盐肤木果实或其提取物在制备防治药物性肝炎肝损伤药物中的应用 Download PDFInfo
- Publication number
- CN113134021A CN113134021A CN202110392889.2A CN202110392889A CN113134021A CN 113134021 A CN113134021 A CN 113134021A CN 202110392889 A CN202110392889 A CN 202110392889A CN 113134021 A CN113134021 A CN 113134021A
- Authority
- CN
- China
- Prior art keywords
- drug
- rhus chinensis
- liver injury
- extract
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000003152 Rhus chinensis Species 0.000 title claims abstract description 44
- 235000014220 Rhus chinensis Nutrition 0.000 title claims abstract description 43
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 40
- 239000000284 extract Substances 0.000 title claims abstract description 33
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 30
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 title claims abstract description 28
- 206010072268 Drug-induced liver injury Diseases 0.000 title claims abstract description 28
- 201000008865 drug-induced hepatitis Diseases 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract description 53
- 206010067125 Liver injury Diseases 0.000 abstract description 32
- 229960005489 paracetamol Drugs 0.000 abstract description 25
- 208000006454 hepatitis Diseases 0.000 abstract description 10
- 235000013305 food Nutrition 0.000 abstract description 9
- 231100000283 hepatitis Toxicity 0.000 abstract description 9
- 239000000469 ethanolic extract Substances 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 239000002994 raw material Substances 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 3
- 239000004278 EU approved seasoning Substances 0.000 abstract description 2
- 235000011194 food seasoning agent Nutrition 0.000 abstract description 2
- 235000018927 edible plant Nutrition 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 231100000439 acute liver injury Toxicity 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000028974 hepatocyte apoptotic process Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000012758 nuclear staining Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000208223 Anacardiaceae Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000208225 Rhus Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了盐肤木果实或其提取物在制备治疗和/或预防药物性肝炎肝损伤药物和保健食品中的应用；本发明通过动物实验对盐肤木果实的提取物防治药物性肝炎肝损伤进行了验证；实验结果证实盐肤木果实的乙醇提取物对对乙酰氨基酚引起的肝炎肝损伤有显著的预防和改善作用；且盐肤木果实是食用植物调味料，安全性高，且分布较为广泛、种植简单、原料易得；综合这些原因，盐肤木果实或其提取物在制备防治药物性肝炎肝损伤的药物和保健食品方面拥有较好的开发利用前景。
Description
技术领域
本发明涉及盐肤木或其提取物在制备治疗和/或预防药物性肝炎肝损伤的保健食品或药品中的应用，属于食品或医药技术领域。
背景技术
肝脏是人体新陈代谢的中心器官，负责对代谢废物、外部物质和/或药物进行解毒，因此其非常脆弱，容易受到损伤。数据显示，肝脏相关疾病(如肝炎、肝硬化、肝癌)的发生十分普遍，全球每年约有200万人死于肝脏疾病。药物性肝损伤(DILI)已成为临床肝病最常见的原因之一，约占药物不良反应的十分之一。对乙酰氨基酚(acetaminophen,paracetamol, APAP)是一种非甾体药物，是目前临床上较常见的治疗感冒、发热的药物。然而，由于过量使用APAP而导致的急性肝损伤占药物性肝损病例的一半以上，并且死亡率高达30%。在推荐剂量下，APAP是相对安全的，但当剂量超过时，会导致急性肝损伤甚至肝衰竭。目前，APAP诱导的肝损伤的治疗是采用N -乙酰半胱氨酸来治疗，但其作用主要体现在中毒的初期，并有明显的副作用，如恶心、呕吐。因此，有必要寻找更安全有效的方法来解决这个问题。
盐肤木(Rhus chinensis Mill.)是漆树科盐肤木属的一种，其果实常被用作饮料、香料和食用果油的天然来源，是一种很有价值的经济树木，而且分布非常广泛。但是，目前尚未有关于盐肤木果实或其提取物对对乙酰氨基酚诱导的肝炎和肝损伤的报道。
发明内容
本发明目的在于提供盐肤木果实或其提取物在医药和保健食品方面的新用途，具体而言就是将盐肤木果实或其提取物应用在制备治疗和/或预防药物性肝炎肝损伤的药物和保健食品中。
本发明通过对乙酰氨基酚诱导的小鼠药物性肝炎肝损伤模型，发现盐肤木果实对对乙酰氨基酚诱导的小鼠药物性肝炎肝损伤具有较好的预防干预作用；经过多重途径证实盐肤木果实或其提取物对药物性肝炎肝损伤有显著的保护作用。
本发明中盐肤木果实提取物是盐肤木果实的80%乙醇提取物。
本发明对盐肤木果实防治药物性肝炎肝损伤进行了系列的研究，证实了盐肤木果实提取物具有确切的预防药物性肝炎肝损伤的功能，因此可用于防治药物性肝炎肝损伤疾病的新药和新保健食品的制备与开发。盐肤木果实提取物用于制备防治药物性肝炎肝损伤的药物和保健食品具有以下这些优势：盐肤木植物可以适应各种恶劣的自然环境，在我国的分布较广，在日常生活中原料易得；并且传统上，盐肤木果实是食用调味料，盐肤木果油是新食品原料，安全性高；提取和制备的工艺流程简单、市场前景可观、蕴藏着较好的社会和经济效应。
与现有技术相比，本发明具有如下优点：
1、本发明为盐肤木果实发掘了新的保健食品或医疗用途，开拓了一个新的研究领域；
2、本发明通过实验发现盐肤木果实80%乙醇提取物在较低剂量下可以有效地预防和改善对乙酰氨基酚引起的肝炎肝损伤疾病，且提取物来自于可食用的天然植物原材料，安全性高。
附图说明
图1是对乙酰氨基酚诱导的小鼠肝损伤及盐肤木果实80%乙醇提取物干预后的小鼠肝脏形态（A图）及病理切片的H&E染色图（B、C图，H&E ×200, ×400），其中C是对照组, M是对乙酰氨基酚诱导模型组，YL是低剂量组（400 mg/kg），YH是高剂量组（800 mg/kg）；
图2是对乙酰氨基酚诱导的小鼠肝细胞凋亡及盐肤木果实80%乙醇提取物干预后的小鼠肝细胞免疫荧光图，图中第一行是tunel染色结果，第二行是细胞核染色结果，第三行是tunel染色结果与细胞核染色结果叠合；其中C是对照组，M是对乙酰氨基酚诱导模型组, YL是低剂量组（400 mg/kg），YH是高剂量组（800 mg/kg）。
具体实施方式
下面结合病理切片和实验实例数据的来进一步的阐述本发明。这些实验的事例仅用于说明本发明，不用于限制本发明的应用范围。在阅读了本发明的记载以后，本领域的科技人员对其等效的各种改动、修改和修饰，都属于本发明权利要求所限定的范围。
实施例1：盐肤木果实乙醇提取物对对乙酰氨基酚引起的小鼠肝炎肝损伤的防治作用
本实施例采用腹腔注射对乙酰氨基酚的方法建立小鼠药物性肝炎肝损伤的模型，通过动物模型实验观察盐肤木果实的80%乙醇提取物对对乙酰氨基酚引起的小鼠肝炎肝损伤的防治作用
1、实验材料
1.1动物
SPF雄性BALB/c小鼠 (20g ± 10%)，湖南斯莱克景达实验动物有限公司。
1.2提取物
盐肤木果实提取物主要采用质量浓度80%的乙醇溶液提取制备，具体方法如下：盐肤木果实采用质量浓度80%的乙醇溶液进行超声提取，提取温度为25℃，料液比g:mL为1:5，提取时间为30min，滤渣复提一次，收集合并滤液，浓缩冻干制得盐肤木果实提取物。
2、方法与结果
2.1造模与检测
雄性BALB/c小鼠都是体重为20g ± 10%的SPF级小鼠，具体是把40只小鼠分成4组（每笼10只），编号如下：Group 1：对照组（以蒸馏水灌胃，C）、Group 2：模型组（以蒸馏水灌胃，M）、Group 3：醇提取物低剂量组400mg/kg（灌胃提取物，YL）、Group 4：醇提取物高剂量组800mg/kg（灌胃提取物，YH）。连续灌胃7天后，所有小鼠禁食12h，然后M组，YL组以及YH组小鼠腹腔注射350mg/kg剂量的APAP（以CMC-Na溶液助溶），C组小鼠腹腔注射相应剂量的CMC-Na溶液。注射12h后，所有小鼠用异氟烷麻醉后取血并离心得到血浆用于后续检测，然后取出肝脏，将肝脏小叶固定用于病理切片分析，剩余的肝脏组织先用液氮冷冻然后放于-80℃；血浆中ALT和AST，以及肝脏组织中SOD、CAT、GSH和MDA用相应试剂盒进行检测。
2.2 结果
2.2.1 盐肤木果实提取物对对乙酰氨基酚引起的小鼠肝炎肝损伤作用的生化指标
各实验组小鼠血浆和肝脏组织生化指标结果如表1所示，相较于对照组C组来说，腹腔注射对乙酰氨基酚（M组）可以极显著引起血浆中ALT和AST的升高，同时肝脏组织中MDA也显著升高，而SOD、CAT和GSH却显著下降，表明对乙酰氨基酚引起小鼠急性肝炎肝损伤。但是与M组相比，提前灌胃盐肤木果实提取物可以明显改善这些指标，特别是高剂量组，血浆中ALT和AST显著下降，肝脏组织中MDA也显著下降， SOD、CAT和GSH显著升高；这些结果说明，盐肤木果实乙醇提取物不论低剂量还是高剂量都可以显著地防治对乙酰氨基酚引起的药物性肝炎肝损伤。
表1 各实验组小鼠血浆和肝脏组织生化指标结果
注：表中所有结果为平均值± SE (n = 10)，同一行不同上标字母表示有显著差异(p < 0.05)，C为对照组，M为模型组，YL为低剂量组，YH为高剂量组。
2.2.2 盐肤木果实提取物对对乙酰氨基酚引起的小鼠肝炎肝损伤作用的病理切片
肝脏的组织病理学表现为肝脏形态和H&E染色。如图1所示，与C组相比，M组肝脏形态变化明显，肝脏损伤明显。在图1A中，C组肝脏表面光滑明亮，为正常肝脏形态，而M组肝脏表面呈白色颗粒状分布。与M组比较，YL组、YH组肝脏形态明显改善，与C组相似。H&E染色(图1B×200)结果也呈现相似的结果: C组肝脏正常，细胞核完整，排列紧密；M组肝细胞核缩小，肝窦周围出现大量的损伤区和坏死细胞；而YL组和YH组的肝脏H&E切片结果显示，肝脏病理损伤明显改善，尤其是YH组改善更加明显。这些肝脏形态学和病理切片结果进一步证实盐肤木果实提取物可以显著地改善对乙酰氨基酚引起的药物性肝炎肝损伤。
2.2.3 盐肤木果实提取物对对乙酰氨基酚引起的小鼠肝细胞凋亡作用的免疫荧光结果
盐肤木果实提取物对对乙酰氨基酚引起的小鼠肝细胞凋亡作用的免疫荧光结果如图2所示，从图中可以看出，与C组相比，M组的凋亡肝细胞明显增多，说明对乙酰氨基酚引起来肝细胞的凋亡，对肝脏造成了严重的损伤；而与M组相比，YL组和YH组的肝细胞凋亡明显减少，尤其是YH组，说明盐肤木果实提取物可以明显改善对乙酰氨基酚引起的肝细胞凋亡，从而防治对乙酰氨基酚引起的小鼠肝炎肝损伤。
综上所述：可以确定盐肤木果实提取物可以有效地治疗和/或预防对乙酰氨基酚引起的小鼠药物性肝炎肝损伤。因此，盐肤木果实或其提取物可以用来开发防治药物性肝炎肝损伤的药物或保健食品。
Claims (2)
1.盐肤木果实或其提取物在制备治疗和/或预防药物性肝炎肝损伤药物中的应用。
2.盐肤木或其提取物在制备治疗和/或预防药物性肝炎肝损伤保健食品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110392889.2A CN113134021A (zh) | 2021-04-13 | 2021-04-13 | 盐肤木果实或其提取物在制备防治药物性肝炎肝损伤药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110392889.2A CN113134021A (zh) | 2021-04-13 | 2021-04-13 | 盐肤木果实或其提取物在制备防治药物性肝炎肝损伤药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113134021A true CN113134021A (zh) | 2021-07-20 |
Family
ID=76811773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110392889.2A Pending CN113134021A (zh) | 2021-04-13 | 2021-04-13 | 盐肤木果实或其提取物在制备防治药物性肝炎肝损伤药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113134021A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109200071A (zh) * | 2018-10-09 | 2019-01-15 | 昆明理工大学 | 盐肤木果实或其提取物的用途 |
| CN112076235A (zh) * | 2019-06-14 | 2020-12-15 | 昆明芳本生物科技发展有限公司 | 盐肤木果实在制备治疗或预防肝纤维化的药物中的应用 |
| CN112076236A (zh) * | 2019-06-14 | 2020-12-15 | 昆明芳本生物科技发展有限公司 | 盐肤木果实在制备治疗或预防非酒精性脂肪肝的药物中的应用 |
-
2021
- 2021-04-13 CN CN202110392889.2A patent/CN113134021A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109200071A (zh) * | 2018-10-09 | 2019-01-15 | 昆明理工大学 | 盐肤木果实或其提取物的用途 |
| CN112076235A (zh) * | 2019-06-14 | 2020-12-15 | 昆明芳本生物科技发展有限公司 | 盐肤木果实在制备治疗或预防肝纤维化的药物中的应用 |
| CN112076236A (zh) * | 2019-06-14 | 2020-12-15 | 昆明芳本生物科技发展有限公司 | 盐肤木果实在制备治疗或预防非酒精性脂肪肝的药物中的应用 |
Non-Patent Citations (2)
| Title |
|---|
| ZIHUAN WU.ET AL: "Rhus chinensis Mill. fruits prevent high-fat/ethanol diet-induced alcoholic fatty liver in rats via AMPK/SREBP-1/FAS signaling pathway", 《JOURNAL OF FUNCTIONAL FOODS》 * |
| 迟玉杰: "《保健食品学》", 31 May 2016, 中国轻工业出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Geng et al. | Preventive and therapeutic effect of Ganoderma lucidum on kidney injuries and diseases | |
| CN106573028A (zh) | 非酒精性脂肪肝疾病预防及治疗用组合物 | |
| CN109200136A (zh) | 一种用于解酒保肝的中药组合物及其应用 | |
| Chatterjee et al. | Include mushroom in daily diet—A strategy for better hepatic health | |
| Park et al. | Hypoglycemic effect of Padina arborescens extract in streptozotocin-induced diabetic mice | |
| CN104689251A (zh) | 一种缓解化学性肝损伤的中药组合物、其制备方法及中药制剂 | |
| CN103405482B (zh) | 柳叶腊梅提取物在制备治疗炎性肠病和减轻化疗药物引起的消化道损伤的药物中的应用 | |
| Wang et al. | Hypoglycemic effect of ethanol and ethyl acetate extract of Phellinus baumii fruiting body in streptozotocin-induced diabetic mice | |
| CN113134021A (zh) | 盐肤木果实或其提取物在制备防治药物性肝炎肝损伤药物中的应用 | |
| CN115006494B (zh) | 一种显脉旋覆花复合解酒组合物、解酒护肝制剂及其应用 | |
| CN115487280B (zh) | 一种用于解酒保肝、促进肝再生的中药组合物及其制剂和制备方法 | |
| CN108570116B (zh) | 黄绿卷毛菇多糖及制备方法和在防治糖尿病中的医用用途 | |
| CN107137416B (zh) | 一种防治非小细胞肺癌的药物组合物 | |
| CN102342962B (zh) | 马齿苋提取物在制备抗肝损伤药物及保健食品中的应用 | |
| CN100496590C (zh) | 治疗脂肪肝的药物及其制备方法 | |
| CN115177702A (zh) | 一种护肝组合物和制备方法及其用途 | |
| Moubarz et al. | Effectiveness of aqueous extract of marjoram leaves in the treatment of aspartame liver toxicity | |
| CN107029173A (zh) | 一种治疗原发性肝癌的药物组合物 | |
| CN110840950A (zh) | 俄色茶和/或俄色茶提取物在制备防治非酒精性肝病和/或非酒精性肝损伤的药品中的应用 | |
| CN110693873A (zh) | 冬凌草活性成分组合物的制备及应用 | |
| CN113384667B (zh) | 一种防治肝损伤和/或肝癌的药物组合物及其制备方法和用途 | |
| CN110433168A (zh) | 裂环环烯醚萜衍生物在制备预防和治疗神经退行性疾病药物中的应用及其组成的药物组合物 | |
| Hu et al. | On the value of apricot kernel in modern medicine and its future development | |
| CN111097024A (zh) | 癣痒膏 | |
| CN112494626B (zh) | 一种具有对化学性肝损伤有保护作用的片剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210720 |
|
| RJ01 | Rejection of invention patent application after publication |